231 related articles for article (PubMed ID: 28326244)
1. Sunitinib resistance in renal cell carcinoma.
Morais C
J Kidney Cancer VHL; 2014; 1(1):1-11. PubMed ID: 28326244
[TBL] [Abstract][Full Text] [Related]
2. Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study.
Oudard S; Geoffrois L; Guillot A; Chevreau C; Deville JL; Falkowski S; Boyle H; Baciuchka M; Gimel P; Laguerre B; Laramas M; Pfister C; Topart D; Rolland F; Legouffe E; Denechere G; Amela EY; Abadie-Lacourtoisie S; Gross-Goupil M
Eur J Cancer; 2016 Jul; 62():28-35. PubMed ID: 27192659
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib rechallenge in metastatic renal cell carcinoma patients.
Zama IN; Hutson TE; Elson P; Cleary JM; Choueiri TK; Heng DY; Ramaiya N; Michaelson MD; Garcia JA; Knox JJ; Escudier B; Rini BI
Cancer; 2010 Dec; 116(23):5400-6. PubMed ID: 21105118
[TBL] [Abstract][Full Text] [Related]
4. Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma.
Lim SH; Hwang IG; Ji JH; Oh SY; Yi JH; Lim DH; Lim HY; Lee SJ; Park SH
Asia Pac J Clin Oncol; 2017 Feb; 13(1):61-67. PubMed ID: 27030134
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib Rechallenge After Other Targeted Therapies in Metastatic Renal Cell Carcinoma Patients: A Single-Center, Retrospective Study.
Nagyiványi K; Budai B; Gyergyay F; Küronya Z; Bíró K; Géczi L
Clin Drug Investig; 2019 Jun; 39(6):577-583. PubMed ID: 30915661
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.
Juengel E; Kim D; Makarević J; Reiter M; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
J Cell Mol Med; 2015 Feb; 19(2):430-41. PubMed ID: 25444514
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant.
Tsuruda M; Yoshino H; Okamura S; Kuroshima K; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
PLoS One; 2020; 15(5):e0232545. PubMed ID: 32379831
[TBL] [Abstract][Full Text] [Related]
8. The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer.
Azijli K; Gotink KJ; Verheul HM
J Kidney Cancer VHL; 2015; 2(4):195-203. PubMed ID: 28326274
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study.
Munárriz J; Reynés G; Sánchez-Lorenzo L; Esteban E; Basterretxea L; de Avila-Lizárraga L; Climent MA; Juan-Fita MJ; Escoín C; Puente J; Cassinello J; Vázquez S; Chirivella I
Cancer Chemother Pharmacol; 2019 Oct; 84(4):781-789. PubMed ID: 31367791
[TBL] [Abstract][Full Text] [Related]
10. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer.
Elgendy M; Fusco JP; Segura V; Lozano MD; Minucci S; Echeveste JI; Gurpide A; Andueza M; Melero I; Sanmamed MF; Ruiz MR; Calvo A; Pascual JI; Velis JM; Miñana B; Valle RD; Pio R; Agorreta J; Abengozar M; Colecchia M; Brich S; Renne SL; Guruceaga E; Patiño-García A; Perez-Gracia JL
Int J Cancer; 2019 Oct; 145(7):1991-2001. PubMed ID: 30848481
[TBL] [Abstract][Full Text] [Related]
11. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
[TBL] [Abstract][Full Text] [Related]
12. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
[TBL] [Abstract][Full Text] [Related]
13. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
[TBL] [Abstract][Full Text] [Related]
14. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
Sakai I; Miyake H; Fujisawa M
BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Wen T; Xiao H; Luo C; Huang L; Xiong M
Oncotarget; 2017 Mar; 8(12):20441-20451. PubMed ID: 28099901
[TBL] [Abstract][Full Text] [Related]
16. From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib.
Abdel-Aziz AK; Abdel-Naim AB; Shouman S; Minucci S; Elgendy M
Front Pharmacol; 2017; 8():718. PubMed ID: 29066973
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).
Motzer RJ; Alyasova A; Ye D; Karpenko A; Li H; Alekseev B; Xie L; Kurteva G; Kowalyszyn R; Karyakin O; Neron Y; Cosgriff T; Collins L; Brechenmacher T; Lin C; Morgan L; Yang L
Ann Oncol; 2016 Mar; 27(3):441-8. PubMed ID: 26681676
[TBL] [Abstract][Full Text] [Related]
18. PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines.
Bender C; Ullrich A
Int J Cancer; 2012 Jul; 131(2):E45-55. PubMed ID: 22020623
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S
Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758
[TBL] [Abstract][Full Text] [Related]
20. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.
Elfiky AA; Cho DC; McDermott DF; Rosenberg JE; Fortner B; Antràs L; Chen K; Sheng Duh M; Jayawant SS; Oh WK; Atkins MB; Choueiri TK
Urol Oncol; 2011; 29(6):756-63. PubMed ID: 20451414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
